Investors Eye Biotech Sector as Cancer Therapy Market Surges

Core Insights - The article discusses the advancements in cancer treatment and detection technologies, highlighting the significant progress made by Oncolytics Biotech Inc. and other biotech companies in 2025 amid rising global cancer rates [1][2][3] Company Developments - Oncolytics Biotech Inc. has made key regulatory and clinical advancements in 2025, particularly with its immunotherapy drug pelareorep, which has received safety and regulatory clearance to advance enrollment in its pancreatic cancer study [3][4] - The company presented new efficacy and safety data for pelareorep at the 2025 ASCO Gastrointestinal Cancers Symposium, showing strong responses in anal cancer and confirming a favorable safety profile in pancreatic cancer [5][6] - Oncolytics is set to advance its pancreatic cancer trial (GOBLET Cohort 5) with 30 patients participating, evaluating pelareorep in combination with modified FOLFIRINOX, with or without atezolizumab [4][5] Industry Trends - The global cancer therapy market is projected to reach approximately $285.96 billion by 2030, with a compound annual growth rate (CAGR) of 9.12%, indicating significant market expansion for advanced oncology solutions [2] - The collaboration between GRAIL, Inc. and Quest Diagnostics aims to improve access to early cancer detection through GRAIL's Galleri test, enhancing provider access via Quest's connectivity system [10][11] - Renovaro Inc. has entered into a binding LOI to acquire Predictive Oncology Inc., which will enhance its capabilities in cancer diagnostics and therapeutics, leveraging Predictive's extensive biobank and AI-driven drug discovery platform [12][13][14]